Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.32 USD
-0.01 (-1.70%)
Updated Sep 20, 2024 03:44 PM ET
After-Market: $0.32 0.00 (-1.45%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KZIA 0.32 -0.01(-1.70%)
Will KZIA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KZIA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KZIA
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
KZIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now
Other News for KZIA
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
Kazia Therapeutics enters into licensing agreement with QIMR Berghofer
Kazia Therapeutics executes licensing agreement with QIMR Berghofer Medical
Kazia Therapeutics files to sell $100M of American Depositary Shares
Kazia Therapeutics files to sell $100M of American Depositary Shares